Clinical characteristics and outcomes of paediatric CNO: a retrospective cohort study with focus on zoledronic acid
Clicks: 2
ID: 325537
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #77 of 198 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 198 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: Chronic non-bacterial osteomyelitis is a rare autoinflammatory bone disease of childhood. Non-steroidal anti-inflammatory drugs are often used first-line, while conventional and biologic disease-modifying antirheumatic drugs and bisphosphonates are reserved for severe or refractory disease. Zoledronic acid is used off-label, but robust data on its role remain limited. This study aimed to describe the clinical characteristics, management, and outcomes of children with Chronic non-bacterial osteomyelitis, with primary focus on the effectiveness and tolerability of Zoledronic acid. METHOD: A retrospective review was conducted of children diagnosed with chronic non-bacterial osteomyelitis between 2014 and 2024 at the Royal Children's Hospital, Melbourne. Clinical and magnetic resonance imaging responses to ZA, as well as adverse effects, were evaluated. RESULTS: Fifty-seven patients were included (mean age 10.3 years; 70% female; median follow-up 3.7 years [range 1.4-8.9]). Multifocal disease was present in 86%, and 63% underwent biopsy. All received non-steroidal anti-inflammatory drugs initially. Twenty-two patients (37%) received zoledronic acid (mean 2.6 doses); 77% showed significant clinical improvement. Three later required tumour necrosis factor inhibitors, and two received tumour necrosis factor inhibitors without prior zoledronic acid. Among 10 patients with pre- and post-zoledronic acid whole body magnetic resonance imaging, 80% demonstrated significant radiological improvement. Mild, transient flu-like symptoms were reported in 54% of patients treated with zoledronic acid; no serious adverse events occurred. CONCLUSION: Zoledronic acid was associated with high clinical and radiological response rates and was well tolerated. Its infrequent dosing schedule, typically one infusion every six months, offers a practical alternative to other bisphosphonates.
| Reference Key |
openalex_W7203777300
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yonatan Herman, Jonathan Akikusa, Julie Jones, Georgina Tiller, Jane Munro, Peter Simm, Margaret Zacharin, Neelika Liyanage, Nisha Varma, William D Renton |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag442
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.